Industrial enzyme maker Novozymes is seeking to strengthen its
presence in the biopharmaceutical market by offering to acquire
Australian biotechnology firm Gropep for AUD83.6m (€49.6m), eager
to become a supplier of recombinant ingredients...
The world's first drug made from a genetically engineered goat has
been given the thumbs up in Europe after being initially rejected
in February. The decision has reopened the door for "pharming,"
where transgenic animals...
Biocrystal has upped the stakes in the cell culture market with
Opticell, a product it claims brakes away from traditional cell
culture concepts and promises to reduce costs through increased
Surmodics has announced that as a result of a collaboration with
the Donaldson Company, the first of a collection of new synthetic
nanofibrillar cell culture surfaces have been produced that will
improve cell culture, cell-based bioassays...
Centocor has enlisted Cardinal Health to use its rapid cell line
development technology to engineer cell lines expressing Centocor's
monoclonal antibodies, and speed up the development of new
Millipore has introduced a new 24-well cell culture plate which has
twice the membrane surface area compared with other 24-well plates,
allowing researchers to utilize greater cell mass, which more
closely models cell behaviour.
In the same week that saw Novartis threaten its planned merger with
Berna Biotech, Dutch biotech company Crucell has signed three new
licensing agreements for its PER.C6 and STAR manufacturing
Dowpharma has announced the addition of an oligonucleotide
synthesizer for its manufacturing of nucleic acid medicines. The
new oligo synthesizer is said to increase speed and flexibility in
producing clinical quantities for customers.
Genetix Limited has launched the ClonePixFL, a mammalian cell
imaging and picking instrument that builds upon the success of the
ClonePix adding fluorescent capabilities to its clone picking
Invitrogen announced it is to acquire Dynal Biotech, the molecular
separation and purification technology company. The deal will
provide Invitrogen with bead-based isolation technologies that
targets key medical research issues.
Australia's CSL, the world's largest manufacturer of blood plasma
products, has agreed to sell its JRH Biosciences division to
Sigma-Aldrich for $370 million (€283m) in cash. JRH makes cell
culture and sera products used...
US biotechnology start-up Cytovance Biologics has officially opened
for business this month, offering a portfolio of process
development services to support biotechnology companies preparing
to progress products into clinical development.